New research from Dana-Farber Cancer Institute shows that a new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint. The evidence gathered in the Oser Lab at Dana-Farber supports testing of the strategy in humans. A phase 1 clinical trial is now open nationwide for patients with small cell lung cancer, triple negative breast cancer, and other cancers.

Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool, called MARLIN (Methylation- and AI-guided Rapid Leukemia Subtype Inference), uses DNA methylation patterns and machine learning to classify acute leukemia with speed and accuracy. This tool has the potential to significantly improve patient care by allowing faster and more precise treatment decisions.

Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments

OncLive® State of the Science Summit™ (SOSS) are in-person meetings designed for academic & community-based physicians and health care professionals that provide education on the science driving updates in cancer management and the associated clinical benefits for patients. SOSS attendees will improve their knowledge of novel treatment approaches and reinforce their confidence in applying state-of-the-art treatment strategies.

The following patient safety experts are unwavering champions for patient harm reduction, disease management and disaster preparedness. Representing various roles across hospitals, health systems and healthcare companies, they all share a common goal of keeping patients safe and satisfied. Safety is the driving mission for these leaders, guiding them to constantly pioneer new approaches, refine […]

Immunotherapy for cancer has made some of its biggest inroads against hematologic malignancies such as leukemia and lymphoma, with treatments such as checkpoint inhibitors and CAR T-cell therapies producing long-lasting remissions in some patients.

News Politics Tech Fact Check Personal Finance Automotive Sports Better Workplaces

Studies show that people receiving tamoxifen, a highly effective and commonly used therapy to treat breast cancer, face a 2- to 7-fold increased risk of developing uterine cancer within 2-5 years of tamoxifen treatment compared to the general population.

New research unveiled in the September 2025 issue of the Journal of the National Comprehensive Cancer Network (JNCCN) sheds transformative light on medication management in older adults with cancer.

Treatment advances are extending the lives, and improving the quality of life, of many patients with ovarian cancer.

Published: May 19, 2025Written by: Lukas Harnisch-WeidauerMedically Reviewed By: Mark Pomerantz, MDAmong cancer diagnoses, prostate cancer is relatively common, especially for those who are older than 65. Fortunately, it is often manageable with minimal interventions necessary for a substantial portion of patients. However, many prostate cancer cases can be categorized as "aggressive," meaning it will require more ... Read more

In this video, we are highlighting one of our new Crazy 8 Initiative funded projects. Every newborn in the United States gets a “heel-stick” blood test to check for certain rare diseases, but cancer risk isn’t included. Led by co-principal investigators Dr. Sharon Plon and Dr. Lisa Diller, this Crazy 8 team will study the implementation and promise of a genetic test using this newborn blood samples, to screen for several cancer predisposition syndromes. The team has identified nine genes that could signal a high risk for early-onset cancers, including the RB1 gene which can cause retinoblastoma, a type of eye cancer. If identified early, babies with a faulty RB1 gene could receive eye exams and treatment before the cancer progresses preserving their eyesight and their lives. The team’s goal is to develop an affordable, AI-supported genetic test to screen newborn blood samples. They will also create educational materials for parents and test them in Boston and Houston to see how parents and pediatricians respond to this new screening. If successful, the research will help push for nationwide adoption of newborn cancer risk screening. Read more about this project ➡️ https://www.alexslemonade.org/project/newborn-screening-early-childhood-cancer-predisposition-syndromes Follow ALSF🍋: Blog: https://www.alexslemonade.org/blog Facebook: https://www.facebook.com/alexslemonade Twitter: https://twitter.com/AlexsLemonade Instagram: https://www.instagram.com/alexslemonade TikTok: https://www.tiktok.com/@alexslemonade

Radioligand therapy is an innovative cancer treatment that uses targeted radioactivity, not chemicals, to damage cancer cells. Learn more.

Published: August 21, 2025Written by: Beth DoughertyFor a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.   ... Read more

Dana-Farber Direct Connect provides guided access to world-renowned expertise from cancer care specialists at Dana-Farber Cancer Institute. Through the Direct Connect program, Dana-Farber will support your employees and clients across the spectrum of oncology needs.